EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?

Christelle Orlando iD, Céline Drèze, Anton Evenepoel, Sara Seneca, Kristin Jochmans

Thrombosis and Haemostasis · 01.04.2026 · 126 (04) · 405-417

DOI: 10.1055/a-2628-4046 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2026. Verfasst von Christelle Orlando und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Hauptthemen laut MEDLINE: Antithrombin III Deficiency, Antithrombin III, Antithrombins, Reagent Kits, Diagnostic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary antithrombin (AT) deficiency is a rare autosomal dominant disorder that predisposes to the development of recurrent venous thromboembolism (VTE). Diagnosis is based on the measurement of reduced AT activity in plasma. However, not all commercial AT activity assays are equally suited for diagnosis since they differ in sensitivity toward different AT mutations. The aim of this study was to compare the ability of commonly used AT activity assays to diagnose inherited antithrombin deficiency, with a focus on type II AT deficiencies. We used samples from genetically confirmed AT deficient subjects (n = 76) and from patients with request for AT activity measurement for diagnostic purposes (n = 152). AT activity was measured with five commercial assays on three analyzers. All reagent/analyzer combinations showed specificities varying from 87 to 100%, except for 1 assay (56.5% specificity). Diagnostic sensitivity varied widely between assays, from 36.8% to 100%. All reagent–analyzer combinations correctly identified variants causing type I AT deficiencies but only one variant responsible for type II heparin binding site (HBS) deficiency: p.Arg79Cys. For one of the assays, we observed a large difference in sensitivity (82.9 versus 55.3%) toward antithrombin type II HBS variants depending on the coagulation analyzer on which it is performed, suggesting that incubation time of sample and substrate could be a crucial driver of the sensitivity toward variants causing type II antithrombin deficiency. Our results suggest that inherited antithrombin deficiency is probably underestimated and improved diagnostic strategies are mandatory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antithrombin III DeficiencyAntithrombin IIIAntithrombinsReagent Kits, DiagnosticHumansBlood Coagulation TestsVenous ThromboembolismMutationSensitivity and SpecificityPredictive Value of TestsReproducibility of Results

Substanzen

Antithrombin IIIAntithrombinsReagent Kits, DiagnosticSERPINC1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Medical Genetics, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

ORCID-Profile: Christelle Orlando

Zitieren

APA

Orlando, C., Drèze, C., Evenepoel, A., Seneca, S., & Jochmans, K. (2026). Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?. Thrombosis and Haemostasis, 126(04), 405-417. https://doi.org/10.1055/a-2628-4046

Vancouver

Orlando C, Drèze C, Evenepoel A, Seneca S, Jochmans K. Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?. Thrombosis and Haemostasis. 2026;126(04):405-417. doi:10.1055/a-2628-4046

BibTeX
@article{Orlando2026,
  author = {Orlando, Christelle and Drèze, Céline and Evenepoel, Anton and Seneca, Sara and Jochmans, Kristin},
  title = {Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {04},
  pages = {405--417},
  doi = {10.1055/a-2628-4046}
}
Kostenlos starten →